Statements (19)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:acquiredBy |
Phoenixus AG
|
| gptkbp:CEO |
gptkb:Martin_Shkreli
|
| gptkbp:country |
gptkb:United_States
|
| gptkbp:formerName |
gptkb:Turing_Pharmaceuticals
|
| gptkbp:foundedBy |
gptkb:Martin_Shkreli
|
| gptkbp:foundedYear |
2015
|
| gptkbp:headquartersLocation |
gptkb:New_York_City
|
| https://www.w3.org/2000/01/rdf-schema#label |
Vyera Pharmaceuticals
|
| gptkbp:industry |
pharmaceuticals
|
| gptkbp:legalIssue |
antitrust law
|
| gptkbp:notableEvent |
price hike of Daraprim in 2015
|
| gptkbp:notablePerson |
gptkb:Martin_Shkreli
Ron Tilles |
| gptkbp:notableProduct |
gptkb:Daraprim
|
| gptkbp:website |
https://www.vyera.com/
|
| gptkbp:bfsParent |
gptkb:Turing_Pharmaceuticals
gptkb:Daraprim |
| gptkbp:bfsLayer |
7
|